Palivizumab does not improve long-term outcomes in kids with cystic fibrosis - Healio

Palivizumab does not improve long-term outcomes in kids with cystic fibrosis  Healio

Palivizumab — a monoclonal antibody that prevents respiratory syncytial virus, or RSV, in high-risk infants — did not improve long-term outcomes like respiratory ...



Comments

Popular posts from this blog

Urinary Tract Infection (UTI): Causes, Symptoms & Treatment - Cleveland Clinic

Rashes that look like scabies: Causes, symptoms, and treatment - Medical News Today